ArticleBMC psychiatry2025
Cognitive impairment and its influencing factors in patients with stable schizophrenia on regular medication: a real-world clinical study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCognitive dysfunction is a core characteristic of schizophrenia, independent of positive and negative symptoms. It significantly impacts social reintegration, quality of life, and imposes a burden on families and society. This study investigates the prevalence and influencing factors of cognitive impairment in patients with stable schizophrenia on regular medication, with the hope of providing assistance to the cognitive improvement of patients.
methodsA multistage stratified sampling approach was implemented to screen and enroll eligible patients with stable schizophrenia from five specialized psychiatric hospitals in Henan Province. Psychiatrists who had received standardized training conducted questionnaire responses and cognitive assessments for the patients, and quality control personnel reviewed the questionnaires. Binary Logistic analysis was used to detect the influencing factors of cognitive function.
resultsThe valid questionnaires of 1,274 patients were collected from January 1, 2022, to December 31, 2023. The cognitive dysfunction rate of the patients with stable schizophrenia on regular medication was 66.2%. The risk factors for cognitive function, in descending order, are: first-generation antipsychotics (FGAs) (OR: 9.246, 95%CI: 1.021,1.093), family history (OR: 2.535, 95%CI: 1.349,4.762), negative symptoms (OR: 2.532, 95%CI: 1.735,3.695), mood stabilizers (OR: 1.882, 95%CI: 1.356,2.613), anticholinergic drugs (OR: 1.616, 95%CI: 1.161,2.249), combined medication (OR: 1.332, 95%CI: 1.009,1.760), high body mass index (BMI) (OR: 1.069, 95%CI: 1.030,1.111), longer duration of education (OR: 1.057, 95%CI: 1.021,1.093), and long duration of disease (OR: 1.045, 95%CI: 1.028,1.063). The protective factors, in descending order, are: taking 5-HT1A receptor partial agonist (OR: 0.657, 95%CI: 0.503,0.857) and having more children (OR: 0.817, 95%CI: 0.732,0.912). The sensitivity of the regression model for predicting cognitive function was 66.5%, and the specificity was 88.0%.
conclusionsFindings highlight the complex interplay of personal, familial, psychiatric, physical, and pharmacological factors in cognitive impairment. Medication use, especially FGAs, significantly influences cognitive function, underscoring the need for psychiatrists to closely monitor treatment regimens to mitigate cognitive decline and improve long-term outcomes in patients with stable schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.